PT-141

Research summary

PT-141 (bremelanotide) is a synthetic peptide related to Melanotan II but more selective, acting primarily on melanocortin-4 receptors in the central nervous system. Bremelanotide is FDA-approved under the brand name Vyleesi for a specific indication in premenopausal women —a regulatory fact noted for research-literature context, not usage guidance.

The RECONNECT program —two Phase 3 randomized, placebo-controlled trials pooling 1,267 premenopausal women —found roughly 25% of bremelanotide-treated women reported meaningful improvement versus 17% on placebo, with effects sustained through a 52-week open-label extension and no new safety signals in long-term follow-up.

Sources: Obstetrics & Gynecology, 2019 (Kingsberg et al.); PubMed 33538638. Findings from published research —not a claim about this product, and not evidence of safety or effectiveness for human use.